An Official Website of the United States Government
Company Information:
Name:
AVANIR PHARMACEUTICALS
Address:
AVANIR PHARMACEUTICALS
11388 SORRENTO VALLEY RD, STE 200
SAN DIEGO, CA 92121 0134
11388 SORRENTO VALLEY RD, STE 200
SAN DIEGO, CA 92121 0134
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
(858) 622-5215
Award Totals:
Award List:
N/A
Award Year / Program / Phase:
2000 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Laura E. Pope
Award Amount:
$100,000.00
DOCOSANOL AND ACYCLOVIR FOR TREATING GENITAL HERPES
Award Year / Program / Phase:
2002 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Laura E. Pope
Award Amount:
$0.00
Abstract:
DESCRIPTION (Provided by applicant): There is a substantial need for a safe,
effective topical treatment for genital herpes simplex (HSV) disease. The
proposed research aims to evaluate feasibility of continued development of
docosanol as a topical treatment for… More
DOCOSANOL AND ACYCLOVIR FOR TREATING GENITAL HERPES
Award Year / Program / Phase:
2002 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Laura E. Pope
Award Amount:
$1,008,843.00
Abstract:
DESCRIPTION (Provided by applicant): There is a substantial need for a safe,
effective topical treatment for genital herpes simplex (HSV) disease. The
proposed research aims to evaluate feasibility of continued development of
docosanol as a topical treatment for… More
Diverse Neutralizing Human Monoclonal Antibodies to CMV
Award Year / Program / Phase:
2003 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Phillip R. Morrow
Award Amount:
$100,000.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this proposal (Phase I and II) is to develop a human monoclonal antibody-based preparation for use in treating CMV infections or transmission. Commercial applications for human monoclonal antibodies are extensive.
Phase I specific aims… More
Diverse mix of Human MoAbs to treat Anthrax exposure
Award Year / Program / Phase:
2003 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Phillip R. Morrow
Award Amount:
$100,000.00
Abstract:
DESCRIPTION (provided by the applicant): The long-term goal of this proposal (phase I and II) is the development of a human monoclonal antibody-based preparation for use in treating B. anthracis (anthrax) exposure or for use prophylactically. This preparation would most likely be composed of… More
Human Antibodies for Exposure/Protection from Anthrax
Award Year / Program / Phase:
2004 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Angray S. Kang
Award Amount:
$750,263.00
Abstract:
DESCRIPTION (provided by applicant): Avanir Pharmaceuticals Inc., has developed a powerful platform for the rapid generation of high affinity fully human monoclonal antibodies that can be selected on their ability to neutralize anthrax toxin PA as exemplified by our lead candidate 8C1 (Kd 1.2… More